Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis

Oscar Fernández
Department of Neurology, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
Corresponding author email: oscar.fernandez.sspa@juntadeandalucia.es

Abstract: Glatiramer acetate (GA) represents one of the most common disease-modifying therapies for multiple sclerosis. GA is currently approved for patients at high risk of developing clinically definite multiple sclerosis (CDMS) after having experienced a well-defined first clinical episode (clinically isolated syndrome or CIS) and for patients with relapsing-remitting multiple sclerosis (RRMS). GA's efficacy and effectiveness to reduce relapse frequency have been proved in placebo-controlled and observational studies. Comparative trials have also confirmed the lack of significant differences over other choices of treatment in the management of relapse frequency, and long-term studies have supported its effect at extended periods of time. Additionally, RRMS patients with suboptimal response to interferon β may benefit from reduced relapse rate after switching to GA, and those with clinically isolated syndrome may benefit from delayed conversion to CDMS. All these results, together with its proven long-term safety and positive effect on patients’ daily living, support the favorable risk-benefit of GA for multiple sclerosis treatment.

Keywords: disease-modifying therapy, glatiramer acetate, multiple sclerosis, relapse
Introduction
Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease affecting young adults, being the most frequent chronic neurological disease in this segment of population. Sometimes it can be detected before any clinical symptoms when a magnetic resonance imaging (MRI) study is done for other reasons (eg, radiological isolated syndrome or RIS); some persons with RIS will convert to MS after some years delay. In the most common cases, there is a first clinical manifestation or relapse typical of a demyelinating disease called clinically isolated syndrome (CIS). After some time, other relapses will ensue, making it possible to establish the diagnosis of clinically definite multiple sclerosis (CDMS). Nowadays, the diagnosis can be done as soon as MRI shows enhancing and not enhancing lesions after the CIS. Later on, patients enter a period of attacks and remissions, so-called relapsing-remitting multiple sclerosis (RRMS). Some 10 to 20 years later, the majority of patients enter a phase of disability progression with or without superimposed relapses called secondary progressive multiple sclerosis (SPMS). This is the typical course for 90% of MS patients; another 10% will have a progressive disease since onset, with or without exacerbations, called primary progressive multiple sclerosis (PPMS).

The approved treatments for MS at present include glatiramer acetate (GA—Copaxone®; Teva Pharmaceutical Ltd.), formerly known as copolymer 1, a peptide mixture of four amino acids initially designed as an analogue of myelin basic protein. Effective in preventing and suppressing experimental autoimmune encephalomyelitis, the primary animal model of multiple sclerosis, in a variety of animals including guinea pigs, rabbits, mice, and monkeys. Early exploratory studies addressed the potential benefit of GA for MS treatment, which was confirmed in a US phase III trial that proved its efficacy in reducing the relapse rate in patients with relapsing-remitting MS (RRMS) without inducing significant side effects. The benefit shown by GA administration to patients with RRMS in these studies finally led GA to being first approved in 1996 in the United States.

Even though the mechanism of action of GA is not completely understood, it has been shown to be an immunomodulatory agent with neuroprotective properties. It also appears to induce GA-reactive Th2 immunoregulatory cells in experimental models of experimental autoimmune encephalomyelitis, which may cross the blood–brain barrier and stimulate the secretion of anti-inflammatory cytokines and growth factors. Additionally, GA has been shown to stimulate secretion of neurotrophins that might protect axons and promote injured neurons to be repaired.

All these properties may contribute to the beneficial effect of GA reported by clinical trials carried out in patients with RRMS either initiating immunomodulatory therapy or switching from IFNβ. Long-term studies confirmed the efficacy and safety of GA during exposure periods extended up to 15 or 22 years, observational studies verified its benefit under clinical practice conditions, and patient-oriented research supported its favorable effect on daily living. In addition, patients with clinically isolated syndrome (CIS) have also been shown to benefit from GA treatment, delaying conversion to clinically definite MS (CDMS). Currently, GA is approved in many countries worldwide for the treatment of patients who have experienced a well-defined first clinical episode and are determined to be at high risk of developing CDMS and for the reduction in frequency of relapses in ambulatory patients with RRMS. This article aims to review the use of GA in patients with RRMS or CIS, mainly in terms of the management of relapse frequency.
Pharmacokinetic Profile, Metabolism, and Mechanism of Action

GA is the acetate salt of a mixture of synthetic poly-peptide composed of L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, with a molar residue ratio 0.14:0.34:0.43:0.09, an average length of 45 to 100 amino acids and a molecular mass of 4.7–11.0 kDa. The pharmacokinetic profile of GA has not been assessed in patients with MS. However, the data available from in vitro studies and those performed in healthy volunteers showed that the active substance was rapidly absorbed, with maximum plasma concentration of 69 to 605 ng/mL, an area under the plasma concentration-time curve from time zero to six hours of 1,644 to 67,532 ng·min/mL, and time to the maximum plasma concentration between 15 and 30 minutes after 60 mg of GA was subcutaneously administered to healthy volunteers. A large part of the dose is rapidly degraded to smaller fragments in subcutaneous tissues, and studies carried out with radiolabeled doses of GA in animal models showed that the highest radioactive levels were in the stomach and thyroid, while the lowest radioactive levels were in the brain, possibly because of the high polarity and hydrophilic nature of GA prevent it from crossing the blood–brain barrier.36 A partial part of the dose is rapidly degraded to smaller fragments in subcutaneous tissues, and studies carried out with radiolabeled doses of GA in animal models showed that the highest radioactive levels were in the stomach and thyroid, while the lowest radioactive levels were in the brain, possibly because of the high polarity and hydrophilic nature of GA prevent it from crossing the blood–brain barrier.36

Even though the mechanism of action has not been completely elucidated, GA is thought to act by immunomodulating the pathways involved in the pathogenesis of MS and inducing both neuroprotective and remyelinating effects (Fig. 1).11 GA has been shown to bind with high affinity to major histocompatibility complex class II molecules present on the surface of myelin basic protein-recognizing antigen presenting cells,37,38 acting either as a blocking peptide or as an antagonist and resulting in suppression of autoimmune T cell response, anergy, or both.38 The binding of GA and major histocompatibility complexes to receptors on T-reactive cells in the bloodstream also triggers T cells to proliferate and secrete cytokines.12 In fact, GA has been shown to induce some populations of GA-specific regulatory CD4+ and CD8+ T cells, as well as to induce a shift towards a Th2 pattern of anti-inflammatory cytokines.39–42 Even though GA does not cross the blood–brain barrier, GA-reactive Th2 cells can do so and can also be reactivated by central nervous system (CNS) antigens such as myelin brain protein, which would induce the expression of anti-inflammatory cytokines that cause bystander suppression.42,43 In addition, GA has been shown to alter B cell function, inducing antibodies against GA.44–46 However, these antibodies have been shown not to compromise GA activity,45,46 but, on the contrary, they have been suggested to enhance remyelination in chronic lesions.47 Furthermore, GA has been demonstrated to act on antigen presenting cells, inhibiting monocyte reactivity,48 exerting an antiproliferative effect of monocyte-derived dendritic cells on lymphocytes,49 modulating monocyte and dendritic function that contribute to Th2 deviation,48,50,51 and triggering the production anti-inflammatory cytokines by monocytes and dendritic cells.49,52

Furthermore, GA has been shown to stimulate secretion of neurotrophins such as brain-derived neurotrophic factor (BDNF) in both animal models and patients with MS,54,55 which might contribute to protect axons and promote injured neurons to be repaired.12 Additionally, GA has also been associated with remyelination through increasing proliferation, differentiation, and survival of oligodendrocyte precursor cells in injury sites.56 The increase in oligodendrocyte precursor cells has been suggested to be associated with elevation of insulin-like growth factor-1 and BDNF, which might be involved in the mechanism of proliferation and maturation of oligodendrocyte precursor cells into oligodendrocytes.57 However, it is still difficult to differentiate whether the reduction in neuronal and myelin injury results

Figure 1. Overview of glatiramer acetate mechanism of action. Abbreviations: APC, antigen-presenting cell; B, B cell; BBB, blood–brain barrier; BDNF, brain-derived neurotrophic factor; GA, glatiramer acetate; MBP, myelin brain protein; OPC, oligodendrocyte precursor cell; T, T cell.
from the release of BDNF or from the blockade of inflammatory pathways.58

**Clinical Studies**

**Efficacy**

Utility of glatiramer acetate versus placebo

The efficacy of GA has been widely evaluated during the last three decades. In 1995, the first data on a Phase III clinical trial evaluating GA’s effect in comparison with placebo was published.10 This was the US pivotal trial of GA in RRMS, a Phase III, randomized, double-blind, placebo-controlled study in which a total of 251 patients diagnosed with RRMS according to Poser’s criteria were randomly assigned (1:1) to receive placebo or GA. The objective of the study was to compare the therapeutic impact and tolerance of daily subcutaneous injections of 20 mg of GA in comparison with placebo over two years, using the number of relapses as the primary endpoint (Table 1). The results obtained showed that the 2-year relapse rate was reduced by 29%, from 1.68 in patients receiving placebo to 1.19 in those receiving GA (P = 0.007), with annualized relapse rates (ARR) for placebo and GA of 0.84 and 0.59, respectively. Trends favoring GA were also noted in the proportion of relapse-free patients (27.0% vs. 33.6%; P = 0.10) and in the median time to first relapse (198 vs. 287 days; P = 0.10).

Another double-blind, randomized, placebo-controlled trial subsequently addressed the effect of GA in comparison with placebo in a European/Canadian population of patients diagnosed with RRMS.15 A total of 239 patients were randomized (1:1) to receive placebo or 20 mg of GA administered as daily subcutaneous injections (Table 1). The analysis of the primary endpoint showed a statistically significant fewer number of enhancing lesions in the GA group (36.8 vs. 26.0; P = 0.003), with a mean reduction of 29% in the patients receiving GA in comparison with placebo (−10.8, 95% confidence interval [CI] −18.0 to −3.7; P = 0.003) and a fewer number of enhancing lesions per patient per month (2.9 vs. 4.1; P < 0.005). Similarly, significant differences supporting the positive effect of GA were also observed in almost all secondary endpoints, including the mean change in enhancing lesion volume (−105.1 μL vs. −245.3 μL; P = 0.01), number of new enhancing lesions (26.0 vs. 17.4; P < 0.003), number of new T2-weighted lesions (13.7 vs. 9.4; P < 0.003) and change in its volume (4.7 mL vs. 3.0 mL; P = 0.006). Even though only six patients in the placebo group and three patients in the GA group were inactive over the entire study, monthly comparisons of groups revealed a positive effect of GA emerging during the third trimester (12.5% vs. 27.7%; odds ratio [OR] 3.86; 95% CI 1.76–8.48; P < 0.001). In fact, the quarterly comparison of scans without any enhancing lesions between placebo and GA showed that the differences became statistically significant during the second (29.9 vs. 39.8; P = 0.03) and third quarters (26.0 vs. 43.8; P < 0.001). Additionally, the mean relapse rate was 33% lower in patients receiving GA (0.76 vs. 0.51; P = 0.01), with an ARR of 1.21 in patients receiving placebo and 0.81 in those treated with GA, and the proportion of relapse-free patients slightly increased, albeit not significantly, when GA was used (49.2% vs. 55.5%; P = 0.18).

Utility of glatiramer acetate versus interferon

Several clinical trials have directly evaluated the efficacy of GA in comparison with IFNβ in patients with RRMS, reporting the lack of significant differences in primary endpoints assessing reductions in relapse rates (Table 1).14,16,17 The REGARD Study was an open-label, randomized, phase IV trial carried out in 764 treatment-naïve patients diagnosed with RRMS according to McDonald criteria who had experienced at least one relapse during the year before being enrolled in the study.16 Patients were randomly assigned (1:1) to receive 44 μg of IFNβ-1a administered subcutaneously three times per week or 20 mg of GA administered subcutaneously once daily. The analysis of the primary endpoint showed that the number of relapses over the 96 weeks of the study was lower than expected in both IFNβ-1a and GA groups (126 vs. 132) and there were no significant differences between treatment groups in the time to the first relapse (hazard ratio [HR] 0.94, 95% CI 0.74, 1.21; P = 0.64). MRI results also showed the absence of significant differences between IFNβ-1a and GA either in the number of T2 active lesions per patient per scan (0.67 vs. 0.82; P = 0.18) or in the mean change in T2 active lesions volume (−2,416.9 mm³ vs. −1583.5 mm³; P = 0.26). Patients treated with IFNβ-1a showed a significant lower number of gadolinium-enhancing lesions per...
Table 1. Summary of glatiramer acetate efficacy versus placebo and interferon β in relapsing-remitting multiple sclerosis.

| Study | Study treatments | Primary outcomes | Secondary outcomes |
|-------|------------------|------------------|--------------------|
| **Placebo-controlled trials: placebo vs. GA** | | | |
| US pivotal trial¹⁰ (N = 251) | 20 mg GA sc, qd | Mean 2-year relapse rate decreased by 29%: placebo 1.68 vs. GA 1.19, *P* = 0.007. | Proportion of relapse-free patients: placebo 27.0% vs. GA 33.6%, *P* = 0.098. |
| | Placebo | Annualized relapse rates: placebo 0.84 vs. GA 0.59. | Median time to first relapse: placebo 198 days vs. GA 287 days, *P* = 0.097. |
| | | 2-year number of relapses: placebo 210 vs. 161 GA. | Proportion of patients with a worsening in disability: placebo 28.8% vs. GA 20.8%, *P* = 0.037. |
| European/Canadian trial¹² (N = 239) | 20 mg GA sc, qd | Mean number of enhancing lesions: placebo 36.8 vs. GA 26.0, *P* = 0.003. | Proportion of patients with disability improvement: placebo 15.2% vs. GA 24.8%. |
| | Placebo | 29% reduction in total number of enhancing lesions: −10.8, 95% CI −10.8–−3.7, *P* = 0.003. | Mean EDSS change: placebo 0.21 vs. GA −0.05, *P* = 0.023. |
| | | Mean number of enhancing lesions per patient per month: placebo 4.1 vs. GA 2.9, *P* < 0.005. | Proportion of progression-free patients: placebo 75.4% vs. GA 78.4%, *P* ≥ 0.05. |
| **Comparative trials: IFNβ vs. GA** | | No significant differences in the time to the first relapse over 96 weeks: HR 0.94, 95% CI 0.74–1.21, *P* = 0.64. | Mean ambulation index: placebo 0.28 vs. GA 0.27, *P* ≥ 0.05. |
| REGARD study¹⁶ (N = 764) | 44 µg IFNβ-1a sc, 3qw | No significant differences in: | Mean change in enhancing lesion volume: placebo −105.1 µL vs. GA −245.3 µL, *P* = 0.01. |
| | 20 mg GA sc, qd | • Mean number of T2 active lesions per patient per scan: IFNβ-1a 0.67 vs. GA 0.82, *P* = 0.18. | • Mean number of new T2-weighted lesions: placebo 26.0 vs. GA 17.4, *P* < 0.003. |
| | | • Mean change in T2 active lesions volume: IFNβ-1a −2,416.9 mm³ vs. GA −1,583.5 mm³, *P* = 0.26. | Mean change in new T2-weighted lesion volume: placebo 4.7 mL vs. GA 3.0 mL, *P* = 0.006. |
| | | • Number of gadolinium-enhancing lesions per patient per scan: IFNβ-1a 0.24 vs. GA 0.41, *P* = 0.0002. | Mean change in hypointense T1 lesion volume: placebo 1.3 mL vs. GA 0.8 mL, *P* = 0.14. |
| | | • Change in volume of gadolinium-enhancing lesions: IFNβ-1a −164.3 mm³ vs. GA −162.6 mm³, *P* = 0.42. | |
| BEYOND study¹⁷ (N = 2,244) | 250 µg IFNβ-1b sc, eod | Relapse risk did not significantly differ between: | No significant differences were observed among 250 µg IFNβ-1b, 500 µg IFNβ-1b and GA groups in: |
| | 500 µg IFNβ-1b sc, eod | • 500 µg IFNβ-1b vs. 250 µg IFNβ-1b: HR 0.93, 95% CI 0.81–1.07, *P* = 0.16. | • Time to the first relapse (25th percentile): 283 vs. 348 vs. 271 days; *P* ≥ 0.05. |
| | 20 mg GA sc, qd | • 500 µg IFNβ-1b vs. GA: HR 0.98, 95% CI 0.82–1.18, *P* = 0.43. | • Proportion of 2-year relapse-free patients: 58% vs. 60% vs. 59%, *P* ≥ 0.05. |
| | | • 250 µg IFNβ-1b vs. GA: HR 1.06, 95% CI 0.89–1.26, *P* = 0.73. | Annualized relapse rate: 0.36 vs. 0.33 vs. 0.34, *P* ≥ 0.05. |
| | | | • Confirmed EDSS progression: 27% vs. 22% vs. 21%, *P* ≥ 0.05. |

(Continued)
Table 1. (Continued)

| Study          | Study treatments | Primary outcomes                                                                 | Secondary outcomes                                                                 |
|----------------|------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| BECOME Study   | 250 µg IFNβ-1b sc, eod 20 mg GA sc, qd | Median (75th percentile) number of combined active lesions per patient and MRI in the first year did not significantly differ between treatments: INFβ-1b 0.63 vs. GA 0.58, P = 0.58. | No significant differences were observed between groups in: Proportion of patients free of new lesions from months 1 to 12: INFβ-1b 19% vs. GA 28%, P = 0.43. Median (75th percentile) number of new lesions per subject per month from months 1 to 12: INFβ-1b 0.46 vs. GA 0.33, P = 0.19. Proportion of patients free of new lesions from months 1 to 24: INFβ-1b 21% vs. GA 21%, P = 1.00. Median (75th percentile) number of lesions per subject per month from months 1 to 24: INFβ-1b 0.46 vs. GA 0.23, P = 0.13. |

Abbreviations: CI, confidence interval; eod, every other day; EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; HR, hazard ratio; IFNβ, interferon β; qd, once a day; sc, subcutaneously; 3qw, three times per week.
primary endpoint was the number of combined active lesions per scan in the first year, defined as the sum of the contrast-enhancing lesions in T1 plus the new T2 lesions on the MRIs that had appeared since the most recent examination. The results obtained showed that patients receiving either IFNβ-1b or GA showed a similar median number of combined active lesions per patient and MRI (0.63 vs. 0.58; \( P = 0.58 \)). From months 1 to 12, no significant differences between INFβ-1b and GA were observed in the proportion of patients free of new lesions (19% vs. 28%; \( P = 0.43 \)) or in the median number of new lesions per subject per month (0.46 vs. 0.33; \( P = 0.19 \)). Similarly, there were no significant differences between these groups either in the number of patients free of new lesions (21% vs. 21%; \( P = 1.00 \)) or in the median number of lesions per subject per month from months 1 to 24 (0.46 vs. 0.23; \( P = 0.13 \)). Additionally, patients receiving IFNβ-1b and GA showed a similar ARR (0.37 vs. 0.33; \( P = 0.68 \)), which decreased from baseline by approximately 79% (from 1.87 to 0.37) and 83% (from 1.9 to 0.23) in patients receiving IFNβ-1b and GA, respectively.

In light of the above, the results achieved in the primary endpoints of these three comparative studies were similar between INFβ-1b and GA treatments, including the time to the first relapse, risk of relapse, and number of combined active lesions. Likewise, similar results between treatments were observed in other variables such as ARR, disease progression, and many MRI assessments (eg, T2-active lesions, volume of gadolinium-enhancing lesions, T1-hypointense lesion volume, and lesion-free patients). In addition, the decreased relapse rate observed in these comparative trials was much greater than in the US pivotal trial.10 The most likely explanation is the existence of differences in patient populations derived from the diagnosis of RRMS according to different criteria, that is, Poser’s criteria in the US pivotal trial and McDonald criteria in comparative trials.59 In fact, the currently used McDonald criteria based on imaging diagnosis techniques rather than in clinical criteria enable MS to be diagnosed and treated earlier. Therefore, the results of the REGARD, BEYOND, and BECOME studies more likely represent the efficacy that might be expected after starting GA treatment in patients newly diagnosed with RRMS.59

Long-term utility of glatiramer acetate
Despite the increasing trend to recommend the initiation of disease-modifying therapies as early as possible, a reduced number of studies have approached the assessment of patients after long-term GA treatment (Table 2).

One of these studies is the open-label extension phase of the US GA pivotal trial, which has reported the effect of GA treatment for 6 years,60,61 8 years,62 10 years,63 and up to 15 years.21 The last data cut-off was performed in February 2008, at which 100 out of the 232 (43.1%) patients who had received at least one dose of GA from the beginning of the trial still remained in the extension phase and the average length of GA treatment was of 13.6 years.21

| Study | Study treatments | Main efficacy outcomes |
|-------|------------------|------------------------|
| **Open-label extension phase of the US pivotal trial up to 15 years**21 (\( N = 232 \)) | 20 mg GA sc, qd | Annualized relapse rate was reduced by 77.7%: before starting GA 1.12 vs 15-year analysis 0.25. Proportion of patients with maintained or improved EDSS scores at 15-year analysis: 57%. Mean EDSS change per year 15-year analysis: 0.1 points. Proportion of patients with EDSS scores of 4, 6 and 8 at 15-year analysis: 38%, 18% and 3%, respectively. |
| **Long-term open-label, compassionate-use study up to 22 years**22 (\( N = 46 \)) | 20 mg GA sc, qd | Annualized relapse rate declined 97%: prior to study 3.06 vs last observation 0.09. Proportion of relapse-free patients throughout GA treatment: 72%. Mean increase in EDSS scores from the study entry: 0.6 points. Proportion of patients with maintained or improved EDSS scores: 67%. |

**Abbreviations:** EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; qd, once a day; sc, subcutaneously.
The results obtained at this data cutoff showed a reduction of 77.7% in the ARR, from 1.12 before starting GA to 0.25 at the 15-year analysis.

Another study assessing long-term effects of GA was performed in 46 patients who received GA as compassionate use for RRMS up to 22 years.22 After a mean duration of GA treatment of 16.3 years, mean ARR also declined significantly from 3.06 prior to study entry to 0.09 at the last observation. Additionally, approximately 72% of patients were still relapse-free throughout the course of GA treatment.

Utility of glatiramer acetate in terms of reducing brain atrophy

Brain atrophy is a well-known phenomenon in patients with MS,64 which may be related to focal tissue damage at earlier points in time and represents the most significant MRI predictor of disability at follow-up.65 Brain volume loss is a dynamic process that mildly affects RRMS patients and usually occurs despite receiving disease-modifying treatments.66 Even though several studies have approached the effect of GA on brain atrophy, the variable results obtained did not enable us to reach clear conclusions.

The short-term assessment of brain loss in patients included in the European/Canadian placebo-controlled trial did not find a significant effect of GA on reducing brain loss in patients with RRMS over an 18-month follow-up period, in which brain volume decreased by 1.4% and 1.2% in patients originally randomized to placebo and GA, respectively.67 Another study carried out in patients with RRMS also reported a decline of 2.0% in the percentage of central brain volume change over a 14-month follow-up, which was correlated with higher scores on the Expanded Disability Status Scale (EDSS) and T2 lesions at baseline.68 Additionally, a recently published study in patients with RRMS or CIS showed a steady decrease in brain volume not explained by changes in inflammation detected in monthly MRI irrespective of IFNβ or GA treatment.69 In fact, an average monthly decrease of 1.3 cm³ was observed in spite of an average transient increase of 1.2 cm³ per lesion resulting from focal inflammatory activity.

In contrast, the US pivotal trial reported a nearly three-fold lower annual decline in brain volume over a 2-year GA treatment in comparison with placebo.70 Similarly, two large randomized comparative trials of IFNβ and GA that included the assessment of

| Study | Study treatments | Main efficacy outcomes |
|-------|------------------|------------------------|
| Caon et al18 | 20 mg GA sc, qd | Annualized relapse rate decreased by 57%, from 1.23 to 0.53 ($P = 0.0001$). Subgroup analyses of annualized relapse rate: |
| (N = 85) | | • Patients switched due to suboptimal response: decrease from 1.32 to 0.52 ($P = 0.0001$). |
| | | • Patients switched due to unacceptable toxicity: decrease from 0.61 to 0.47 ($P \geq 0.05$). |
| | | EDSS scores improved from 3.50 to 3.08 ($P = 0.0001$). |
| Zwiebel20 | 20 mg GA sc, qd | A total of 558 patients were treatment-naïve and 247 patients switched from IFNβ at baseline. Patients switching from IFNβ: |
| (N = 805) | | • Annualized relapse rate decreased by 75%. |
| | | • Proportion of relapse-free patients during the study: 68.4%. |
| | | • Mean changes in EDSS scores from baseline < 0.5 points. |
| Carra et al19 | IFNβ-1b | Patients switched from a low-dose IFNβ to high-dose IFNβ (n = 31), to GA (n = 52) or to mitoxantrone (n = 13); and from GA to IFNβ (n = 16) or mitoxantrone (n = 2). |
| (N = 114) | 22 µg IFNβ-1a im | Patients switched from IFNβ to GA: |
| | 44 µg IFNβ-1a im | • Annualized relapse rate decreased by of 77%, from 0.63 to 0.14. |
| | 12 mg/kg mitoxantrone | • Proportion of relapse-free patients increased from 38% to 73%. |
| | GA | • EDSS scores remained stable (mean change, 0.17; $P = 0.27$). |

| Abbreviations: EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; IFNβ, interferon β; im, intramuscularly; qd, once a day; sc, subcutaneously. |
changes in brain volume showed lower decreases in whole brain volume during the first year of treatment with GA. However, one of them did not detect such significant differences among treatments during the second and third years of treatment, while the other still detected lower brain volume loss during the second year of GA treatment. In both studies, the magnitude of brain volume loss was greater at the beginning of the treatment, which might partly be associated with a reduction in inflammatory edema (pseudoatrophy) that was more prominent in IFN-β associated with a reduction in inflammatory edema beginning of the treatment, which might partly be prevented. In addition, a recently published comparison of RRMS treatments such as the administration of 30 μg of IFN-β intramuscularly every week, 250 μg of IFN-β subcutaneously every other week or 20 mg of GA subcutaneously once a day over a 5-year period showed that GA enabled the least brain volume loss in comparison with high-dose IFN-β (−2.62% vs. −2.27%; P = 0.004) and low-dose IFN-β (−3.21% vs. −2.27%; P < 0.001).

The variable results obtained in the above-mentioned studies might be partly derived from differences in study designs and durations, which may not be adequate to reveal beneficial effects in a chronic disease like MS. Thus, further research on brain volume variation is still needed to clarify the effect of GA treatment.

Utility of switching from interferon to glatiramer acetate
Several studies have been performed to address the effect of switching the treatment from IFN-β to GA in patients with suboptimal response to IFN-β, which showed clear improvements in relapse rates (Table 3).

The first was a prospective observational study carried out in 85 patients with RRMS who had received weekly intramuscular doses of IFN-β-1a for at least 18 months. These patients switched to GA because of persisting suboptimal response (n = 62) or unacceptable toxicity (n = 23) to IFN-β. The analysis of the primary endpoint showed that GA enabled ARR to be reduced from 1.23 to 0.53 (P < 0.001) after an average of 37.5 months on treatment. Subgroup analyses showed that this reduction was statistically significant in patients who were switched because of suboptimal response (1.32 vs. 0.52; P = 0.001) but did not reach statistical significance in those who were switched because of unacceptable toxicity (0.61 vs. 0.47; P ≥ 0.05).

A subsequent prospective open-label study was conducted in a heterogeneous population of patients with RRMS who received GA on a compassionate-use basis, which included a cohort of patients who had discontinued IFN-β-1b as a result of inadequate response or toxicity. A total of 805 patients were enrolled into the study: 558 treatment-naïve patients and 247 patients previously treated with IFN-β-1b. Patients who had previously received IFN-β-1b were older, showed more advanced disease, and reported greater disability according to EDSS scores at baseline. ARR decreased by 75% in both treatment-naïve patients and those previously receiving IFN-β-1b after an average duration of GA treatment of 20.3 months and 14.8 months, respectively. In addition, 69.5% of treatment-naïve patients and 68.4% of patients previously treated with IFN-β-1b remained relapse-free throughout the 3.5 years of the study. The median time to the first relapse was 1391 days for treatment-naïve patients and could not be estimated for prior IFN-β-1b patients because 50% of these patients had not relapsed by the study end.

Another prospective observational study carried out in 114 patients with RRMS assessed the impact on clinical outcomes of switching immunotherapy in patients who did not respond adequately to initial treatment or experienced unacceptable side effects. Patients were switched from a low-dose IFN-β to high-dose IFN-β (n = 31), to GA (n = 52), or to mitoxantrone (n = 13) and from GA to INF-β (n = 16) or mitoxantrone (n = 2). All groups obtained benefit from switching the treatment over the 3-year post-switch treatment period. However, the best results were obtained after switching to GA or mitoxantrone in terms of improving ARR, increasing the proportion of relapse-free patients, and the stabilization of
EDSS scores. In fact, patients whose treatment was switched from IFNβ to GA even reached a reduction in the ARR of 77%, from 0.63 to 0.14, and the proportion of relapse-free patients increased from 38% to 73%.

Utility of glatiramer acetate in clinical practice

Even though clinical trials provide strong evidence, their strictly controlled conditions and homogeneous patient populations may entail differences in the effectiveness and safety observed in clinical practice. This fact has reinforced the need to perform observational studies worldwide in order to assess the effect of GA in routine clinical practice.

Two database analyses of large populations of patients with MS under treatment with intramuscular IFNβ or GA have addressed the use of these drugs in US institutions. The results obtained showed that the use of GA was associated with a significantly lower estimated 2-year risk of relapse in comparison with IFNβ-1a, which reached 5.18% and 10.01% ($P = 0.003$), respectively. The mean time to the first relapse did not significantly differ among patients receiving IFNβ-1a, IFNβ-1b, or GA (189.9 days vs. 187.8 days vs 193.7 days; $P \geq 0.05$). However, the one-year relapse risk was greater in patients under treatment with IFNβ-1a (HR 1.147; $P = 0.003$) or IFNβ-1b (HR 1.512; $P = 0.005$).

A German study also compared immunomodulatory treatments for RRMS such as intramuscular IFNβ-1a, subcutaneous IFNβ-1a, IFNβ-1b, and GA administered under clinical practice conditions using a structured clinical database. The relapse rate was reduced to a comparable extent with all regimens after six months of treatment. However, the reduction achieved after 24 months was greater in patients receiving GA ($-0.81; P < 0.001$), reaching values of 0.80 for intramuscular IFNβ-1a, 0.69 for IFNβ-1b, 0.66 for subcutaneous IFNβ-1a, and 0.36 for GA. The proportion of relapse-free patients after 24 months was also greater, albeit not significantly, in patients receiving GA, with percentages of 35.4%, 45.5%, 45.8%, and 58.2% in patients receiving intramuscular IFNβ-1a, IFNβ-1b, subcutaneous IFNβ-1a, and GA, respectively.

The results obtained in a Spanish cohort of patients with RRMS treated with GA for two years showed a 65.2% reduction in the relapse rate, which was 58.3% in the subgroup of patients that switched from IFNβ because of suboptimal response. At the second year of treatment, the proportion of relapse-free patients was 46.6%. Similarly, another observational study carried out in a Spanish population of 104 patients with CDMS or RRMS was recently published showing the beneficial effect of GA administration under clinical practice conditions in terms of both relapse rate and disease progression. In fact, the relapse rate was reduced by 60% (1.0 vs. 0.4; $P < 0.001$) and 70% (1.0 vs. 0.3; $P < 0.001$) during the first and second years of treatment. This reduction enabled 68.4% and 75.9% of patients to be relapse-free during these two years of treatment, respectively. The analysis of a subgroup of patients who had been previously treated with INFβ also showed reductions in relapse rate of 60% (1.0 vs. 0.4; $P = 0.008$) and 64% (1.1 vs. 0.4; $P = 0.02$) during the first and second year on GA treatment, respectively. These results supported effectiveness of GA treatment in clinical practice conditions.

Utility of glatiramer acetate in the clinically isolated syndrome

The PreClSe trial was a randomized, double-blind, placebo-controlled, phase III trial that aimed to assess the effect of GA on conversion to CDMS in patients with CIS. A total of 481 patients were enrolled in the study and randomly assigned (1:1) to receive daily subcutaneous injections of 20 mg of GA or placebo. The analysis of the primary endpoint showed that patients receiving GA attained a 45% reduction in the risk of conversion to CDMS during the placebo-controlled phase of the study (HR 0.5, 95% CI 0.40–0.77; $P = 0.001$). In fact, a delay of 386 days (115%) was observed in conversion to CIS for first quartile of patients under treatment with GA in comparison with those receiving placebo (722 vs. 336 days). The proportion of patients having a second attack was also reduced from 42.9% in the placebo group to 24.7% in the GA group (OR 0.41, 95% CI 0.28–0.62; $P < 0.001$). Additionally, GA was shown to improve MRI and magnetic resonance spectroscopy outcomes. Patients receiving GA experienced a 58% decrease in the number of new T2-weighted lesions (1.8 vs. 0.7; risk ratio [RR] 0.42, 95% CI 0.29–0.61; $P < 0.001$), as well as a reduced T2-weighted lesion volume (geometric means ratio 0.75, 95% CI 0.64–0.87; $P < 0.001$) and cumulative
number of new T2-weighted lesions (9.8 vs. 4.2; RR 0.47, 95% CI 0.37–0.61; \( P < 0.001 \)). Similarly, patients receiving GA showed a reduced number of both gadolinium-enhancing lesions (RR 0.40, 95% CI 0.30–0.55; \( P < 0.001 \)) and new T1 hypointense lesions (3.6 vs. 1.7; RR 0.42, 95% CI 0.31–0.56; \( P < 0.001 \)). No significant difference in the percentage change from baseline in brain atrophy was noted between patients receiving placebo and GA (–0.38% vs. –0.33%; \( P = 0.05 \)). However, magnetic resonance spectroscopy showed that GA enabled cerebral neuroaxonal integrity to be improved in comparison with placebo, with significant differences in paired changes in N-acetylaspartate between placebo and GA at month 12 (–0.33 vs. 0.14; \( P = 0.03 \)), which tended to be maintained at month 24 (–0.23 vs. 0.17; \( P = 0.15 \)). The favorable results achieved in the PCIS study led GA to be approved by the Food and Drug Administration (FDA) and European Medicine Agency (EMA) for the treatment of CIS.

Safety

Long-term studies have confirmed the safety profile of GA administration in patients with RRMS.\(^{21,22,60–63}\) In fact, results from the follow-up of RRMS patients included in the US pivotal trial up to 15 years showed that the adverse events thought to be related to GA were as expected according to previously published information.\(^{21}\) These adverse events included local reactions at the injection site such as erythema, pain or edema, and symptoms of self-limiting immediate post-injection reactions such as vasodilatation, chest pain, palpitation, tachycardia, or dyspnea. No immune diseases, immunosuppression, or malignancies were reported to be associated with GA. Neither was there evidence of hematologic, hepatic or renal dysfunction, nor emergence of time-dependent adverse events. Additionally, the analysis of reasons for patient discontinuation showed that only 23 (9.9%) out of the 232 patients who had received at least one dose of GA withdrew because of adverse events. The remaining reasons for discontinuation comprised lost to follow-up (\( n = 14 \)) and patient decision/other (\( n = 95 \)), which included patient perception of disease worsening (\( n = 29 \)), desire to switch or combine therapies (\( n = 26 \)), difficulty/ability/unwillingness to adhere to study protocol (\( n = 32 \)), and pregnancy (\( n = 8 \)). Similarly, the results obtained from the long-term, compassionate-use study of GA up to 22 years in RRMS patients showed similar adverse events to those previously reported, mainly including injection site reactions such as soreness, redness, swelling, or itching.\(^{22}\) Six patients who had taken GA up to 22 years also reported the occurrence of lipoatrophy, but no one reported skin necrosis over the course of the study. Only two (4.4%) patients discontinued because of adverse events (immediate post-injection reactions), while other reasons for discontinuation included patient withdrawal of consent (\( n = 15 \)), protocol violations (\( n = 5 \)), patient desire to try another therapy (\( n = 3 \)), pregnancy (\( n = 1 \)), and lost to follow-up (\( n = 1 \)). Furthermore, the adverse events reported in patients with CIS were consistent with the known safety profile of GA, including injection-site reactions in 135 (56%) patients and immediate post-injection reactions in 47 (19%) patients as the most frequently reported adverse events.\(^{24}\) Other adverse events reported irrespective of being related to GA, such as lymphadenopathy, urticaria, influenza-like illness, constipation, pruritus, erythema, vomiting, rash, and blurred vision, were described in up to 5.3% of patients. A low number of withdrawals was also reported in patients with CIS, reaching only 14 (5.8%) patients.

Some anecdotal reports have informed that during treatment with GA, some other side effects may seldom occur, including nausea, joint pain, severe muscle tension or spasticity, impotence, or decreased interest in sex.

Economic advantages

Cost variations among countries have been described as a result of differences in the cost of patients’ care, drug usage and clinical practice, as well as because of variations in the estimates of cost-effectiveness and the lack of homogeneity in the studies’ design.\(^{75}\) However, overall favorable results have been obtained in the budget impact and cost-effectiveness analyses performed comparing GA with other immunomodulatory agents. These favorable results might be helpful to optimize health resources and improve budget control of MS treatment.

Assessment of immunomodulatory therapies for RRMS through a model constructed from the perspective of US health care showed that GA was the best strategy of the four immunomodulatory therapies
used for RRMS, with incremental costs per quality-adjusted life-years (QALY) of $416,301, $303,968, $310,691, $258,465 for subcutaneous IFNβ-1a, intramuscular INFβ-1a, IFNβ-1b, and GA, respectively. Additionally, another model for US health care showed that subcutaneous IFNβ-1a, IFNβ-1b and GA had the most favorable cost per relapse avoided ($80,589, $87,061 and $88,310, respectively) in contrast to intramuscular INFβ-1a, whose cost-effectiveness ratio was the least favorable ($141,721). The total 2-year costs of these treatments were estimated to be $52,010, $50,389, $48,473 and $49,068 for IFNβ-1b, subcutaneous IFNβ-1a, intramuscular INFβ-1a, and GA, respectively. Two additional database analyses also approached the costs of these treatments in the US, reporting lower costs during GA treatment. Indeed, the use of GA represented a 7% reduction in total 2-year direct medical costs in comparison with intramuscular INFβ-1a ($44,201 vs. $41,121; \( P < 0.05 \)). When IFNβ-1a, IFNβ-1b, and GA were compared, this last treatment showed significantly lower annual costs in terms of study therapy ($7,547 vs. $7,648 vs. $6,740; \( P < 0.001 \)), total medications ($7,992 vs. $8,083 vs. $7,256; \( P < 0.001 \)), and total MS-related costs ($9,957 vs. $10,185 vs. $9,522). Furthermore, the comparison of GA and natalizumab in the US through a model developed with patients diagnosed with RRMS showed that GA was associated with cost saving. The estimated lifetime direct medical costs were $422,208 for natalizumab and $408,000 for GA. Compared with symptomatic management, the incremental costs per QALY were calculated to be of $606,228 and $496,222 for natalizumab and GA, respectively.

Further analyses in several countries have recently addressed the cost-effectiveness of immunomodulatory therapies for MS. A budget impact analysis of first-line treatments of RRMS considering a Spanish cohort of 22,255 patients was recently published addressing the costs of both IFNβ and GA. The results obtained showed a mean global budget impact per year of €260,775,470, with an average cost per patient of €11,540 per year. The exclusion of GA would increase the budget impact by 3.2% (€8,419,214; €372 per patient per year). The analysis of the hypothetical scenario in which one treatment would only be administered, the lower budget impact would be obtained with GA (mean annual budget impact per patient, €9,715). A later study assessing the first-line treatments of RRMS in Spain showed that GA (€322,510) was the least costly strategy during the 10-year time-horizon of the study, followed by intramuscular IFNβ-1a (€329,595), IFNβ-1b (€333,925), and subcutaneous IFNβ-1a (€348,208). The average cost per patient for these disease-modifying therapies were €42,454, €47,532, €48,752, and €65,475, respectively. The health benefits provided by these treatments ranged from 4,117 QALY per patient with GA to 4,177 QALY per patient with intramuscular IFNβ-1a. This last treatment was a dominant strategy compared with subcutaneous IFNβ-1a and IFNβ-1b, but it was not considered cost-effective in comparison with GA since the incremental costs per QALY gained with intramuscular IFNβ-1a exceeded the €30,000 per QALY threshold commonly used in Spain. The comparison of costs between the treatment with GA and fingolimod has been recently addressed in a Spanish model (unpublished data). The cost for the first year of treatment with GA was €9,439 in contrast to €19,602 with fingolimod, reaching a difference of €10,163, which represented a 2.1 times higher cost of fingolimod than GA. Additionally, a recently published Italian survey of MS costs which also included natalizumab reported direct costs per patient per year of €9,501 for intramuscular IFNβ-1a, €8,553 for IFNβ-1b, €11,255 for 44 mg of subcutaneous IFNβ-1a, €9,883 for 22 mg of subcutaneous IFNβ-1a, €8,174 for GA, and €21,817 for natalizumab, representing GA the least expensive biological disease-modifying agent for MS treatment.

**Place in Therapy and Patient Preference**

MS treatment has considerably evolved in the last decades. However, GA and IFNβ still remain the main treatment choices for patients with RRMS. New drugs have been approved recently, but, despite having proved their short-term efficacy, their long-term safety profile has not been completely clarified.

Natalizumab is a recombinant humanized anti-α4-integrin antibody recently indicated as single disease-modifying therapy in patients with highly active RRMS despite treatment with INFβ. The approval of this monoclonal antibody by the EMA in 2006 generated considerable optimism especially for patients with active disease in spite of being under
first-line treatment in whom advancing therapy to natalizumab represents a logical approach for disease management. However, the initial excitement was tempered by the unexpected development of progressive multifocal leukoencephalopathy. Additionally, a primary central nervous system lymphoma (PCNSL) has also been reported in a 40-year-old patient after 21 infusions of natalizumab administered as monte-therapy. Since the prevalence of PCNSL in patients with MS is low and the patient was otherwise not immunocompromised, the association between natalizumab treatment and PCNSL cannot be ruled out. The occurrence of opportunistic infections and malignancies also represents a conspicuous concern either on natalizumab or other new emerging therapies for MS treatment.

Cladribine is an antineoplastic and immunosuppressive substance currently indicated for the treatment of hairy cell leukemia. However, the EMA declined approval for it to be used in patients with MS in October 2010 because it considered that the risks in patients under this treatment might not compensate the benefits.

Fingolimod is a sphingosine 1-phosphate receptor modulator approved by the EMA in 2011 as single disease-modifying therapy in patients with highly active RRMS despite treatment with IFNβ and for those with rapidly evolving severe RRMS. This approval enabled the first oral treatment for MS to be available for patients with RRMS. However, its introduction in the market has been gradual and slower than expected because of its higher annual cost and practical inconveniences derived from heart monitoring before and after the first dose.

The main handicap for these therapies is the occurrence of adverse events. However, other factors such as the appearance of neutralizing antibodies may also represent an important drawback. In fact, therapy-induced neutralizing antibodies are a major problem for IFNβ treatment, since they might seriously compromise its biologic activity. These neutralizing antibodies may be induced in up to 35% of patients under treatment with IFNβ and reduce its efficacy on relapses and MRI lesions, particularly at high titers. Additionally, persistent antibodies against natalizumab were detected in about 6% of natalizumab-treated patients, which might be associated with infusion-related adverse events and efficacy loss.

The overall safety of GA and the absence of neutralizing antibodies that compromise its activity represent important advantages for MS treatment. GA efficacy and effectiveness under routine clinical practice conditions have also been widely proved in patients with RRMS. In these patients its efficacy has been shown to be comparable to IFNβ and its long-term effect has also been confirmed. RRMS patients with suboptimal response to IFNβ may also benefit from switching to GA, and patients with CIS under treatment with GA may delay their conversion to CDMS. Additionally, administration of GA may favorably affect disabling symptoms of MS such as depression, fatigue, and spasticity that might interfere with patients’ work performance and other activities of daily living. In fact, GA does not negatively affect depression, which is why GA is the treatment choice for patients with history of depression and might even exert an antidepressant effect through its neuroprotective and anti-inflammatory activity. GA has also been shown to decrease fatigue and work absenteeism as well as to improve spasticity in patients with RRMS previously treated with IFNβ. These effects might impact on patients’ perception of their quality of life. Even though data on health-related quality of life are still scant, the results obtained from a recently published study approaching its assessment in RRMS patients receiving GA in daily clinical practice confirmed early gain in health-related quality of life in treatment-naïve patients after 6 months of treatment that was sustained at 12 months. Early discontinuation of treatment precluded patients from improving health-related quality of life, which might be explained by the prevention of the full effect of GA, as relapse reduction usually occurs after six months of treatment. Therefore, optimal adherence to therapy must be ensured to improve both treatment outcomes and quality of life. The major reasons for treatment discontinuation are patient decision, lost to follow-up, and the occurrence of adverse events. Additionally, several factors such as high levels of self-efficacy, hope, perceived health care provider support, and no previous use of other immunomodulators have been associated with enhanced adherence to GA, while greater level of disability, spasticity, and problems with literacy may negatively influence
adherence. Predictors of adherence might differ between treatment-naïve patients and those switching from IFNβ to GA, so previous experience should also be considered when tailoring interventions to increase adherence to treatment and further research is encouraged to overcome potential barriers.

Taken together, the proven safety, efficacy, effectiveness, and effect on daily living make GA a preferable choice for patients diagnosed with RRMS and those with CIS at high risk of developing CDMS. Furthermore, the cost-effectiveness studies confirmed that GA represents an efficient treatment alternative for MS in comparison with other therapeutic alternatives. These facts reinforce the important role of GA in the treatment of MS.

The emergence of new treatments might conspicuously change the therapeutic approach to MS in the near future. Even though greater efficacy might be achieved with these treatments, their risk-benefit balance considering their long-term efficacy and safety must be carefully analyzed. In fact, data from clinical trials and previous experience in therapeutic areas different from MS have proved that the use of some emerging therapies might entail the occurrence of opportunistic and community-acquired infections, malignancies, and autoimmune diseases. The effect and length of these complications might be unpredictable, which might considerably compromise the attempts to make safe and reasonable decisions about MS treatments. Therefore, the use of GA in the future would not only depend on its risk-benefit analysis but also in the risk-benefit analysis of emerging treatments such as drugs currently approved for the treatment of other diseases, new biological agents, and other drugs currently under development.

Conclusions

The current data available support the continuous use of GA from the initial first-line treatment after the diagnosis of CIS to its prolonged administration during the course of RRMS to reduce the occurrence of relapses. The studies addressing the direct comparison of GA and IFNβ have shown a similar effect in the management of RRMS relapse frequency. In addition, the reduction in relapse rate during GA administration has been shown to be greater in more recently published trials than that observed in the US GA pivotal trial. The magnitude of reduction in relapse rates shown in more recent trials could be considered more representative of the effect that might be obtained after starting GA for the early treatment of RRMS at present. Furthermore, patients with suboptimal response to IFNβ may also benefit from reducing relapse rates after switching to glatiramer acetate.

GA has been shown to have an overall safety profile both in patients with CIS and during long-term administration to patients with RRMS. No opportunistic infections, malignancies, or immune-mediated disorders were reported. However, the occurrence of immediate post-injection reactions and local injection-site reactions associated with GA still need to be followed up.

In conclusion, the proven efficacy of GA for CIS and RRMS, its comparable effects to other treatment choices, and its favorable safety profile over long-term periods support the positive risk-benefit of GA for the treatment of MS. However, the future of GA will not only depend on its own risk-benefit balance but also on the risk-benefit analysis of other emerging therapies.

Acknowledgements

Medical writing support was provided by Esther Álvarez-García at Dynamic S.L. during the preparation of this paper, funded by TEVA Pharma S.L.U. Responsibility for opinions, conclusions, and interpretation of data lies with the author.

Author Contributions

Conceived and designed the manuscript: OFF. Analyzed the data: OFF. Wrote the first draft of the manuscript: OFF. Contributed to the writing of the manuscript: OFF. Agree with manuscript results and conclusions: OFF. Jointly developed the structure and arguments for the paper: OFF. Made critical revisions and approved final version: OFF.

Funding

Medical writing support provided by Dynamic S.L. was funded by TEVA Pharma S.L.U. No other external funding was provided for the preparation of this manuscript.
Competing Interests

The corresponding author (Oscar Fernández, MD, PhD) has received honoraria as consultant in advisory boards, and as chairmen or lecturer in meetings, and has also participated in clinical trials and other research projects promoted by Biogen- Idec, Bayer-Schering; Merck-Serono, Teva, Almirall, Allergan and Novartis.

Disclosures and Ethics

As a requirement of publication author(s) have provided to the publisher signed confirmation of compliance with legal and ethical obligations including but not limited to the following: authorship and contributorship, conflicts of interest, privacy and confidentiality and (where applicable) protection of human and animal research subjects. The authors have read and confirmed their agreement with the ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. Any disclosures are made in this section. The external blind peer reviewers report no conflicts of interest. Provenance: the authors were invited to submit this paper.

References

1. Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett. 1996;50(1-2):1-15.
2. Keith AB, Arnon R, Teitelbaum D, Caspary EA, Wisniewski HM. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci. 1979;42(2):267-74.
3. Sela M, Arnon R, Teitelbaum D. Suppressive activity of Cop 1 in EAE and its relevance to multiple sclerosis. Bull Inst Pasteur. 1990;88:303-14.
4. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Glatiramer acetate: suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1(4):242-8.
5. Teitelbaum D, Fridkis-Harel M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol. 1996;64(2):209-17.
6. Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol. 1982;11(3):317-9.
7. Bornstein MB, Miller AI, Slaghe S, Arnon R, Sela M, Teitelbaum D. Clinical trials of copolymer I in multiple sclerosis. Ann N Y Acad Sci. 1984;436:366-72.
8. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-relapsing multiple sclerosis. N Engl J Med. 1987;317(7):408-14.
9. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. Preliminary report. J Neuroscl. 1977;31(3):433-8.
10. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
11. Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev. 2007;6(7):469-75.
12. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol. 2008;255 Suppl 1:26-36.
13. Aharoni R, Kayban P, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A. 2003;100(24):14157-62.
14. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN-beta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976-83.
15. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging—measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49(3):290-7.
16. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REBif vs. Glatiramer Acetate in Relapsing MS Disease [ REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology. 2008;7(10):903-14.
17. O’Connor P, Filippi M, Aronson B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology. 2009;8(10):889-97.
18. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2006;13(5):471-4.
19. Carra A, Onaha P, Luectg G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurology. 2009;15(4):386-93.
20. Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Acta Neurologica Scandinavica. 2006;113(6):378-86.
21. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010;16(3):342-50.
22. Miller A, Spada V, Beerkircher D, Krestman RR. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2008;14(4):494-9.
23. Castelli-Haley J, Olein-Burkey MA, Lage MJ, Johnson K. Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts. J Med Econ. 2010;13(3):464-71.
24. Fernandez-Fernandez O, Garcia-Trujillo L, Guerrero-Fernandez M, et al. The effectiveness of glatiramer acetate in clinical practice: an observational study. Rev Neurol. 2012;54(1):1-9.
25. Haas J, Firlaff M. Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurology. 2005;12(6):425-31.
26. Olleンドorf DA, Jinikáicia E, Olein-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469-76.
27. Valencia Sánchez C, García Pracek S, Casanova Peño I, et al. Experiencia clínica con tratamiento con acetato de glatirámero en esclerosis múltiple remitiente recurrente. Nefrología. 2011;31 Suppl 2:184.
28. Jørgen PJ, Lehnick D, Sanders E, et al. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes. 2010;8:133.
29. Moca-Lallana JE, de Mingo-Casado P, Amorín-Díaz M, Martínez-Navarro ML, Barreiro AF. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Clin Ther. 2010;32(6):1061-1066.

Journal of Central Nervous System Disease 2012:4
50. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differ
132
in patients with relapsing-remitting multiple sclerosis switching from interferon-beta to glatiramer acetate: the Escala Study. J Neurol Sci. 2012;315(1–2):123–8.

33. Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-
34. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISE study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503–11.

32. Tsai SJ. Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Med Hypotheses. 2007;69(1): 145–8.

31. Metz LM, Pattnet SB, Archibald CJ, et al. The effect of immunomodula-
0.132
tory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry. 2004;75(7):1045–7.

51. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differ-
0.200
entiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;72(11):7144–53.

30. Meca-Lallana JE, Balseiro JJ, Lacruz F, et al. Spasticity improvement in
0.300
patients with relapsing-remitting multiple sclerosis switching from interferon-beta to glatiramer acetate: the Escala Study. J Neurol Sci. 2012;315(1–2):123–8.

52. Berger D, Molnar SB, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A. 2009;106(11):4355–9.

53. Aharoni R, Eilam R, Domev H, Labunsky S, Gela M, Arnon R. The immuno-
0.530
modulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A. 2005;102(52):19045–50.

54. Blanco Y, Moral EA, Notta M, et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett. 2006;406(3):270–5.

55. Tse SK, Wong LP, Chui HL, et al. Effects of glatiramer acetate on the immune system of multiple sclerosis patients. J Neuroimmunol. 2005;167(1–2):137–43.

56. Aharoni R, Hershkovitz A, Eilam R, et al. Demyelination arrest and remyelina-
0.560
tion induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. J Immunol. 2004;172(11):7144–53.

57. van Warmelo M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol. 1998;160(9):4386–97.

58. Duda PW, Schmied MC, Cook SL, Krieger JJ, Halter DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000;105(7):967–76.

59. Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest. 2002;109(5):641–9.

60. Miller A, Shapiro S, Gershtein R, et al. Glatiramer acetate (Copaxone) induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler. 2008;14(6):749–58.

61. Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from Th1 helper to Th2 helper 2 cells. Proc Natl Acad Sci U S A. 2000;97(13):7452–7.

62. Hestvik AL, Skorstad G, Price DA, Vartdal F, Holmoy T. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127(Pt 6):1370–8.

63. Weber MS, Starck M, Wagenpfel S, Meini E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127(Pt 6):1370–8.

64. Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol. 2006;143(2):357–62.

65. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differ-
0.650
entiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172(11):7144–53.

66. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol. 2003;170(9):4483–8.

67. Kadir D, Molnar SB, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A. 2009;106(11):4355–9.

68. Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi M. Clinical and therapeutic efficacy. Mult Scler. 2000;6(4):255–66.
72. Rovaris M, Filippi M. Interventions for the prevention of brain atrophy in multiple sclerosis: current status. CNS Drugs. 2003;17(8):563–75.

73. Arnold DL, Narayan A, Antel S. Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCIsE trial. Mult Scler. 2008;14:S10 [abstract 17].

74. Rocca MA, Comi G, Carra A. Treatment with glatiramer acetate reduces T1 and T2-weighted magnetic resonance imaging activity in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2008;14:S176 [P501].

75. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. CNS Drugs. 2004;18(9):561–74.

76. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245–261.

77. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15(7):543–55.

78. Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. Appl Health Econ Health Policy. 2009;7(2):91–108.

79. Sanchez-De la Rosa R, Sabater E, Casado MA. Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Rev Neurol. 2011;53(3):129–38.

80. Sanchez-De la Rosa R, Sabater E, Casado MA, Arroyo R. Cost-effectiveness analysis of disease modifying drugs (interferons and glatiramer acetate) as first line treatments in relapsing-remitting multiple sclerosis patients. J Med Econ. 2012;15(3):424–33.

81. Berto P, Amato MP, Bellantonio P, et al. The direct cost of patients with multiple sclerosis: a survey from Italian MS centres. Neurol Sci. 2011;32(6):1035–41.

82. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol. 2009;8(6):545–59.

83. Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol. 2009;65(4):367–77.

84. Schweikert A, Kremer M, Ringel F, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009;66(3):403–6.

85. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005;12(11):817–27.

86. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.

87. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391–403.

88. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci. 2009;277 Suppl 1:S37–41.

89. Hadjimichael O, Vollmer T, Oleen-Burkey M. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100.

90. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012.

91. Fraser C, Hadjimichael O, Vollmer T. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2001;33(5):231–9.

92. Fraser C, Morgante L, Hadjimichael O, Vollmer T. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. J Neurosci Nurs. 2004;36(3):120–9.

93. Zwibel H, Parola G, Smith S, Denney D, Oleen-Burkey M. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. J Neurol. 2011;258(3):402–11.